[CAS NO. 2375421-09-1] SR-717 lithium
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [2375421-09-1]
Store
Catalog
SLK-S0853
Brand
Selleck
CAS
2375421-09-1
DESCRIPTION [2375421-09-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 351.19 |
| Molecular Formula | C15H8F2LiN5O3 |
| SMILES | O=C([O-])C1=CC(F)=C(F)C=C1NC(C2=NN=C(N3C=CN=C3)C=C2)=O.[Li+] |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8475 mL | 14.2373 mL | 28.4746 mL |
| 5 mM | 0.5695 mL | 2.8475 mL | 5.6949 mL |
| 10 mM | 0.2847 mL | 1.4237 mL | 2.8475 mL |
| 50 mM | 0.0569 mL | 0.2847 mL | 0.5695 mL |
Description
SR-717 lithium is a non-nucleotide agonist that demonstrates broad interspecies and interallelic specificity with EC50 of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 (cGAS KO) cell lines, respectively. SR-717 lithium also induces the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner. SR-717 lithium exhibits antitumor activity.
Targets
In vitro
SR-717 induces the expression of PD-L1 in THP1 cells and in primary human peripheral blood mononuclear cells in a STING-dependent manner.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.